Vanda Pharmaceuticals Inc.
NASDAQ:VNDABiotechnology
-$0.20 today
- Market cap
- $230.39M
- Beta
- 0.60
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$4.03
Volume 0.83M
Average 1.29M
VNDA EBITDA Margin
EBITDA as a percentage of revenue.
Vanda Pharmaceuticals Inc.NASDAQ: VNDA
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin narrows to -86.8%
EBITDA Margin was -86.8% in Q1 FY2026, down 24.6 pp from a year earlier. On a trailing-twelve-month basis it was -62.6%, down 41.0 pp year over year. Over 3 fiscal years it narrowed by 64.2 pp.
Context
- EBITDA Margin widened in 0 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 4 analysts of -57.4% for the fiscal year ending Dec 2026, up from -58.6% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -86.8%-30.6 pp QoQ
- Last fiscal yearDec 2025
- -58.6%-51.2 pp YoY
- LTMMar 2026
- -62.6%-41.0 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -58.6%
- Year-over-year change
- -51.2pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -58.6% | -51.2pp |
| FY2024 | 2024-12-31 | -7.4% | -12.3pp |
| FY2023 | 2023-12-31 | 4.9% | -0.7pp |
| FY2022 | 2022-12-31 | 5.5% | -11.3pp |
| FY2021 | 2021-12-31 | 16.8% | — |
EBITDA Margin vs competitors
How VNDA compares with its peers on the latest reported figures
- VNDA's LTM Mar 2026 EBITDA Margin of -62.6% is the highest of the 5 companies compared; the peer median is -1590.9%.
- Its year-over-year change of -41.0 pp is the highest of 5, against a peer median of -1537.7 pp.
- Over three fiscal years its change of -64.2 pp compares with a peer median of -189.2 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -62.6% | -41.0 pp | -64.2 pp | |
| LTM Mar 2026 | -148.9% | -100.7 pp | -100.7 pp | |
| LTM Mar 2026 | -308.4% | -186.1 pp | -189.2 pp | |
| LTM Mar 2026 | -2873.3% | -2889.4 pp | — | |
| LTM Mar 2026 | -3956.7% | -3182.9 pp | -1247.4 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
SGMTSagimet Biosciences Inc. | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding VNDA) | -1590.9% | -1537.7 pp | -189.2 pp | |
Competitors are the stored peer set for VNDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 268.68M | 254.38M | 192.64M | 198.77M | 216.11M |
| Cost of Revenue | 25.63M | 24.28M | 14.8M | 11.31M | 13.04M |
| Gross Profit | 243.05M | 230.1M | 177.84M | 187.46M | 203.06M |
| Gross Margin | 90.5% | 90.5% | 92.3% | 94.3% | 94.0% |
| Research & Development | 75.36M | 85.77M | 76.82M | 74.43M | 109.27M |
| Selling, General & Admin | 124.05M | 136.49M | 112.88M | 146.41M | 237.95M |
| Operating Expenses | 200.89M | 223.77M | 191.8M | 228.12M | 354.23M |
| Depreciation & Amortization | 2.84M | 2.73M | 3.01M | 8.13M | 11.92M |
| EBITDA | 45.21M | 14.03M | 9.35M | (14.79M) | (126.73M) |
| EBITDA Margin | 16.8% | 5.5% | 4.9% | -7.4% | -58.6% |
| Operating Income | 42.17M | 6.33M | (13.95M) | (40.66M) | (151.17M) |
| Operating Margin | 15.7% | 2.5% | -7.2% | -20.5% | -70.0% |
| Interest Income | 199K | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 199K | 4.97M | 20.29M | 17.74M | 12.52M |
| Income Before Tax | 42.36M | 11.3M | 6.34M | (22.92M) | (138.65M) |
| Pre-Tax Margin | 15.8% | 4.4% | 3.3% | -11.5% | -64.2% |
| Income Tax Expense | 9.21M | 5.03M | 3.83M | (4.02M) | 81.83M |
| Net Income | 33.15M | 6.28M | 2.51M | (18.9M) | (220.47M) |
| Net Margin | 12.3% | 2.5% | 1.3% | -9.5% | -102.0% |
| EPS (Basic) | 0.60 | 0.11 | 0.04 | (0.32) | (3.74) |
| EPS (Diluted) | 0.58 | 0.11 | 0.04 | (0.32) | (3.74) |
| Weighted Avg Shares | 55.55M | 56.46M | 57.38M | 58.15M | 58.93M |
| Weighted Avg Shares (Diluted) | 56.92M | 56.98M | 57.56M | 58.15M | 58.93M |
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
Intrinsic Alpha fair value
Locked
Current Price
$3.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.